MWNA
WX

Marshall Wace North America’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Marshall Wace North America’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		$343K Hold
8,932
– – 0.01% 583
2013
Q3 		$245K Buy
+8,932
New +$212K 0.01% 535

Other funds holding WX

Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
CI Investments Inc
CI Investments Inc Toronto, Ontario, Canada $20.6B AUM 29.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marshall Wace North America's WX Position: Q4 2013 in Review

Marshall Wace North America held its WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) position steady in Q4 2013 at 8,932 shares worth $343K. The position accounts for 0.01% of the portfolio, ranked #583.

Marshall Wace North America first reported a position in WX in Q3 2013 and has held it in 2 quarters since. 164 funds tracked by Wall St. Rank hold WX as of Q4 2013.

  • Marshall Wace North America held 8,932 shares of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS worth $343K as of Q4 2013.
  • Marshall Wace North America left its WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS share count unchanged in Q4 2013.
  • WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS made up 0.01% of Marshall Wace North America's portfolio in Q4 2013, its #583 holding.
  • Marshall Wace North America first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2013 and has held it in 2 quarters since.
  • 164 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2013.

Based on Marshall Wace North America's 13F filing for Q4 2013, filed 14 Feb 2014.